Posts Tagged ‘Curacao’

Pew Applauds New Caribbean Shark Sanctuaries

FacebookTwitterGoogle+Share

St. Maarten, the Cayman Islands, Curacao, and Grenada boost regional protections for sharks

MAHO, St. Maarten, June 15, 2016 /PRNewswire-HISPANIC PR WIRE/ — Sharks are safer across the Caribbean Sea, with the announcement of four new shark sanctuaries in the region. Prime Minister William Marlin of St. Maarten and Wayne Panton, minister of financial services, commerce, and environment for the Cayman Islands today announced that their exclusive economic zones (EEZs) are completely closed to commercial shark fishing. Additionally, Curacao and Grenada announced that they will establish legislation this year that will protect sharks in their waters.

Photo – http://photos.prnewswire.com/prnh/20160615/379765

Government leaders were joined by ocean advocate Sir Richard Branson, as well as by global shark experts and representatives from The Pew Charitable Trusts and other nongovernmental organizations, at a press conference in St. Maarten to champion the new protected areas.

“People from all over the world come to our island to dive and snorkel with our marine wildlife, including sharks and rays,” said Irania Arrindell, St. Maarten’s minister of tourism, economic affairs, transport, and telecommunications. “St. Maarten’s shark sanctuary will help to ensure that our local shark populations exist for future generations and continue to benefit St. Maarten’s marine ecosystem and ecotourism.”

Together, the two new sanctuaries cover a total of 46,190 square miles (119,631 square kilometers), raising the total number of Caribbean sanctuaries to seven.

Sir Richard Branson, Virgin Unite founder, said: “We applaud the steps taken by Caribbean island governments to conserve sharks in their waters. To these governments, sharks are worth far more alive than dead. We are delighted and encouraged to see this bold action being taken to protect Caribbean ecosystems and bolster ecotourism industries.”

“St. Maarten and the Cayman Islands have joined a progressive group of leaders in global shark conservation by choosing to fully protect the diverse but vulnerable shark and ray species found in their waters,” said Luke Warwick, director of Pew’s global shark conservation campaign. “We look forward to continued expansion of shark conservation in the Caribbean to secure the region as a safe haven for threatened shark species.”

The announcement came during a three-day shark conservation symposium co-hosted by the government of St. Maarten, the St. Maarten Nature Foundation, the Bahamas National Trust, and The Pew Charitable Trusts. At the symposium, Caribbean leaders had the opportunity to learn from global shark experts, such as Boris Worm, professor in marine conservation biology at Dalhousie University in Halifax, Nova Scotia, and discuss shark conservation and shark-related tourism in their jurisdictions.

Since 2009, Pew has worked with governments around the world to establish shark sanctuaries in their territorial waters. The creation of these sanctuaries in the Caribbean brings the total number of sanctuaries worldwide to 14, covering 6 million square miles (15.5 million square kilometers), an area bigger than Canada.

Worldwide, at least 100 million sharks are killed each year in commercial fisheries; nearly 30 percent of all known shark species assessed by scientists are threatened with extinction. Sharks play an important role in maintaining the health of the entire ocean, but they grow and reproduce slowly, which makes them particularly vulnerable to overfishing. Officials in many coastal and island nations recognize sharks’ high value to the dive tourism industry.

“Establishing sanctuaries to protect all sharks makes clear that these top predators warrant the same status as other vulnerable marine wildlife that help attract ecotourism, such as turtles and whales,” Warwick added.

The Pew Charitable Trusts is driven by the power of knowledge to solve today’s most challenging problems. Learn more at www.pewtrusts.org.

Barbara Cvrkel, +1 202-510-5670
bcvrkel@pewtrusts.org

Click Here for More Information »

Cutting edge therapy for Psoriasis patients now available in the Caribbean

- Clinical trials with over 3,000 treated patients demonstrate its efficacy.

- Studies demonstrated that at least two thirds of the patients obtained 75% improvement of Psoriasis Activity Severity Index.

- This treatment significantly improves the quality of life of patients with moderate to severe plaque psoriasis.

PANAMA CITY, Dec. 2, 2015 /PRNewswire-HISPANIC PR WIRE/ – Psoriasis is a chronic skin disease that affects around 140 million people worldwide.  It’s more frequent between the ages of 15 and 25, but may develop at any age and highly impacts the quality of life.

Several types of psoriasis exist, which range from mild to severe and disabling. Plaque psoriasis is the most common form and is known for producing inflammation and scaly patches of thickened skin called “plaques”. It is caused due to a problem in the immunologic system, where white blood cells that normally become activated to fight infections, are in this case activated against the healthy skin cells.  The cause of the disease is unknown. The immunologic system is activated and produces inflammatory mediators which are responsible for the skin lesions.

During this process, white blood cells release chemical products called “cytokines”, which produce inflammation, reddening of the skin and make the cutaneous cells move from deeper skin layer to surface at a higher speed than normal, (almost 5 times). These cells accumulate and generate the scaly patches. Psoriatic lesions show the aspect of scales, sometimes with a white silver color, while the skin below is red and if scratched it can bleed. Two specific cytokines are increased in the pathogenesis of psoriasis and produce the inflammatory process of the disease (Interleukin 12 and Interleukin 23).

Ustekinumab is a monoclonal antibody that represents the first of a new class of psoriasis therapies that specifically and selectively targets IL-12/IL-23.

Ustekinumab is now available in the Caribbean, specifically in Aruba, Bahamas, Bermuda, Cayman Islands, Curacao and Jamaica.[i] Ustekinumab is commercialized under the brand Stelara™.

This therapeutic alternative is the latest generation of psoriasis treatment. With over 3,000 treated patients (in clinical trials) up to 5 years of treatment. The data obtained proves that the treatment is well tolerated and safe.

Clinical trials demonstrated that at least two thirds of the patients obtained a 75% improvement of the psoriasis, in accordance with the Psoriasis Activity Severity Index (PASI 75), after only two doses of Ustekinumab. This innovative treatment has a very convenient dosage regimen when compared with other biological therapies for psoriasis. After 5 years, approximately 80% of the patients treated with Ustekinumab maintain response.

Until recent years, psoriasis was considered a disease limited to the skin. Recent evidence, from important population studies in psoriatic patients, has demonstrated an increase in mortality and a decrease in life expectancy between 3 to 4 years in patients with psoriasis.

On the other hand, the impact of psoriasis notably influences the quality of life, and this is reflected in the increase of different social and psychoactive pathologies, and in the acquisition of unhealthy habits like tobacco and alcohol, favored by low self-esteem, anxiety, depression and the isolation which patients feel subjected to.[ii]

“Ustekinumab significantly improves the quality of life of patients with moderate to severe psoriasis, as well as their physical and mental functions. After 12 weeks of treatment, patients treated with Ustekinumab present a significant improvement in their mental well-being and their physical condition”, affirmed Dr. Eduardo Franco; Janssen’s Medical Director for Central America and the Caribbean.

The itching and pain, the plaques in their hands and feet may hinder the performance of certain tasks or participation in some activities. Overtime, about 40% of psoriatic patients develop arthritis. “The most severe cases of psoriasis may even generate immobility of the patient. Some patients compare the reduction of their physical activities to the ones generated by other diseases as cancer or heart diseases”, pointed out Dr. Jose Antonio Herrera, Immunology Medical Manager for Janssen.

About Janssen

Janssen is a Company dedicated to the research of providing innovative products that help protect and improve the life of people, and face and solve the most important and unresolved medical needs of our times, in the areas of oncology, immunology, neurosciences and infectious, cardiovascular and metabolic diseases.

Across the different companies of the Johnson & Johnson group, our people are united in the passionate pursuit of solutions through science, in benefit of the patients.

Present in over 50 countries, we share the commitment of the founders of the Company, of innovating in ideas, products and services for the patients of the whole world.

[i] Ustekinumab was approved by the following Health Authorities:
Aruba: Drug Registration Board,
Curacao; Drug Registration Board
Jamaica: Ministry of Health.
Cayman Islands, Bahamas and Bermuda are not regulated countries.

[ii] 2009 Latin American Psoriasis Consensus, treatment guides, Latin American Psoriasis Society

Fact Sheet Psoriasis

  1. Psoriasis is a chronic disease that affects over 140 million people worldwide.
  2. It presents itself more frequently between the ages of 15 and 25, but may develop at any age and highly impacts the quality of life.
  3. The main cause for this disease is unknown. The immunologic system is activated and produces inflammatory mediators which stimulated white cells and infiltrate the skin layers. The deep layer cells move to the outer layer of the skin at least 5 time faster than usual, and this produces the characteristic plaque of the psoriasis.
  4. There are several clinical forms of the disease, plaque psoriasis being the most common form. It is known for producing inflammation and scaly patches of thickened skin called “plaques”.
  5. Moderate to severe plaque psoriasis, notably influences the quality of life.  Severe cases of psoriasis may even generate immobility of the patient.
  6. Some patients compare the reduction of their physical activities to the ones generated by other diseases such as cancer or heart disease.
  7. Ustekinumab is now available in the Caribbean, specifically in Aruba, Bahamas, Bermuda, Caiman Islands, Curacao and Jamaica.[i]  Ustekinumab is commercialized under the brand Stelara™.
  8. Clinical trials with over 3,000 patients treated with Ustekinumab have demonstrated its efficacy. At least two thirds of the patients obtained a 75% improvement of the Psoriasis Activity Severity Index.
  9. After 5 years, approximately 80% of the patients treated with Ustekinumab maintain response.

[i] Ustekinumab was approved by the following Health Authorities:
Aruba: Drug Registration Board,
Curacao; Drug Registration Board
Jamaica: Ministry of Health.
Cayman Islands, Bahamas and Bermuda are not regulated countries.

CONTACT:  Janssen, JoanTownsend, (507) 64306252 or (507) 3989740, tojoa

Click Here for More Information »

Prime Minister of Curacao to Address Caribbean Basin Coastal Surveillance and Maritime Security Summit

LONDON, Feb. 28, 2013 /PRNewswire/ — Daniel Hodge, the Prime Minister of Curacao is set to address Defence IQ’s Caribbean Basin Coastal Surveillance and Maritime Security Summit (CABSEC) on the 12 – 14 March 2013 in Curacao: http://www.cabsecevent.com

The participants including ambassadors, defence ministers, senior government officials, chiefs of navies, defence staff and coast guards involved in regional and hemispheric security will discuss maritime security priorities and enforcement requirements for the region: http://www.cabsecevent.com

With the European Union drawing up its Joint EU-Caribbean strategy, the USA strengthening security along this major drug route and Brazil and other Latin American nations increasing efforts to secure this crucial export route, CABSEC comes at an important time for maritime security in the region. Solutions to the regions’ maritime security challenges and funding streams will also be under discussion.

Senior officials will attend the CABSEC Summit including:

  • H.E. Mario Zamora Cordero, the Minister for Public Security of Costa Rica
  • H.E. Ambassador Larry Palmer, the U.S. Ambassador to Barbados and the Eastern Caribbean
  • H.E. Ambassador Robert Kopecky, the Head of Delegation of the EU to Guyana, Suriname, Trinidad and Tobago, and the Dutch Overseas Countries and Territories
  • H.E. Ambassador Adam Blackwell, Secretary of Multidimensional Security, Organization of American States
  • H.E. Lucita Moeniralam, the Netherlands Ambassador to Trinidad and Tobago
  • Vice Admiral Edwin Dominici, Chief of Staff, The Navy of the Dominican Republic
  • Lieutenant General Guy Thibault , Chair of Inter-American Defence Board (IADB), Organization of American States
  • Major General Kenrick Maharaj, Chief of Defence Staff, Trinidad and Tobago Defence Force
  • Major General Richard Foster, Deputy Commander (Continental), Canadian Joint Operations Command
  • Major General Rene Osorio, Chief of Joint Staff, Armed Forces of Honduras

The CABSEC Summit includes a dedicated focus day on Counter-Narcotics, providing international perspectives on tackling the illicit traffic in narcotics and its global implications.

CABSEC will be attended by industry leaders and businesses with solutions to enhance coastal surveillance and maritime security. Sponsors include Damen Shipyards, Aerodata AG, Beechcraft Corporation, Venezuelan firm Aviaservice; Spanish defence giant Indra Sistemas, Swedish defence and security company Saab and Swedish Space Corporation, fastest-growing Canadian defence contractor Provincial Aerospace, along with Alphatron, Esri, OCEA and Pon Power and Caterpillar.

Notes:

CABSEC: 12 – 14 March, Curacao.

Click Here for More Information »

Insel Air Strengthens Competitive Edge as UATP Merchant

WASHINGTON, Feb. 21, 2013 /PRNewswire/ — Insel Air International B.V., Willemstad, Curacao, has joined the UATP Network as a Merchant and now accepts all UATP corporate cards, a move which will provide their corporate travelers their desired form of payment.

(Logo:  http://photos.prnewswire.com/prnh/20081118/NETU022LOGO )

Insel Air’s mission is to generate greater connectivity within the Pan-American region. Accepting UATP for payment will help achieve this vision by giving their corporate clients more choice when traveling to one of their 16 international destinations.

“Partnering with UATP allowed us to address the needs of our growing corporate client base while simultaneously providing Insel Air with the payment solutions needed to remain competitive in this market,” said Jurgen Lippinkhof, chief commercial officer, Insel Air. “Building UATP into our business plan will support our focus on successfully capturing market share.”

“The corporate travel market is quickly expanding, increasing the need for additional payment options,” said Ralph Kaiser, president and CEO, UATP. “Accepting UATP positions Insel Air to capture the growing corporate client market.”

Insel Air is an IOSA certified airline and member of ALTA. They began operations in 2006 with the focus of connecting the Pan-American region, while concentrating on safety, on-time performance and customer service. Insel Air has a fleet of 11 aircrafts that operate approximately 46 flights a day.

UATP is the low cost payment network privately owned by the world’s airlines. For more information, visit http://uatp.com or http://www.fly-inselair.com/

About UATP

UATP is a global payment solution owned and operated by the world’s airlines and accepted by thousands of merchants for air, rail, hotel, cruise and travel agency payments. UATP offers easy-to-use tools, DataStream SM and DataMine SM which provide comprehensive data to Issuers and Corporate Subscribers for accurate travel management.

UATP accounts are accepted as a form of payment for corporate business travel worldwide by airlines, travel agencies and Amtrak®. UATP accounts are issued by: Aeromexico; Air New Zealand (ANZFF.PK); American Airlines (AAMRQ.PK); Austrian Airlines; China Eastern Airlines (NYSE: CEA); Delta Air Lines (NYSE: DAL); EL AL Israel Airlines; Etihad Airways; GOL Linhas aereas inteligentes S.A. (NYSE: GOL and Bovespa: GOLL4); Hahn Air; Japan Airlines (9201:JP); Malaysia Airlines; Qantas Airways (QUBSF.PK); Shandong Airlines; United Airlines (NYSE: UAL); and US Airways (NYSE: LCC).

Click Here for More Information »